Skip to main
AARD
AARD logo

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aardvark Therapeutics has developed ARD-101, a promising oral small-molecule agonist targeting Bitter Taste Receptors, which is currently undergoing a Phase 3 clinical trial for treating hyperphagia associated with Prader-Willi Syndrome (PWS). The product candidate offers a potential competitive edge by triggering the release of multiple hormones involved in the hyperphagia pathway, which is a critical area of unmet medical need where existing therapies have shown limited effectiveness. Financial projections suggest that ARD-101 could achieve worldwide sales of $1.5 billion by 2033, reflecting strong market potential and anticipated meaningful uptake due to the demand for more effective treatments in this therapeutic space.

Bears say

Aardvark Therapeutics Inc. faces a negative outlook primarily due to the limited clinical evaluation of its product candidate ARD-101, which has only been tested in a small sample of 18 patients. The Phase II trial, while showing some positive initial results, employed an open-label study design that raises questions about the robustness and reliability of the findings, compounded by the necessity to control for potential bias in screening responses. Additionally, despite the low probability of safety concerns due to minimal oral bioavailability, the incomplete understanding of ARD-101's safety profile might hinder market confidence and future investment prospects.

AARD has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Strong Buy based on their latest research and market trends.

According to 1 analysts, AARD has a Strong Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.